Dr Reddys Lab launches Naloxone Hydrochloride Injection

Dr Reddy's Laboratories Ltd announced the launch of Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) single-dose prefilled syringe, a therapeutic equivalent generic version of Narcan (Naloxone Hydrochloride) Injection USP, approved by US Food and Drug Administration (USFDA).

This is the company’s second product launch in the market, which has been designated as a competitive generic therapy (CGT) by USFDA. With a CGT designation, the company has 180-day CGT exclusivity to market this product.

Naloxone Hydrochloride Injection is indicated for the complete or partial reversal of opioid depression, including respiratory depression, induced by natural and synthetic opioids including propoxyphene, methadone and certain mixed agonist-antagonist analgesics: nalbuphine, pentazocine, butorphanol and cyclazocine. Naloxone Hydrochloride is also indicated for the diagnosis of suspected or known acute opioid overdosage.

As per the data released by IQVIA Health, Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) had US sales of approximately $31 million MAT for the most recent twelve months ending in January 2020.

Dr Reddy's Naloxone Hydrochloride Injection USP, 2 mg/2 ml (1 mg/ml) is available in 2 ml single-dose prefilled syringe.

On Thursday, the stock of Dr Reddy’s opened at Rs 2,623.95 and slipped 6.4 per cent to Rs 2,497.60 in the early morning trading session on BSE. Later it got closed at Rs 2622.75.